Dabrafenib/Trametinib Combo Shows Long-Term Survival Benefit in Metastatic Melanoma

Source: Specialty Pharmacy Times, July 2019

First-line treatment with dabrafenib (Tafinlar) and trametinib (Mekinist) provided overall survival (OS) and long-term progression-free survival (PFS) benefits in patients with unresectable or metastatic BRAF-mutation positive melanoma, according to a pooled analysis of 2 phase 3 trials.

Metastatic melanoma often results in poor prognosis for patients who are diagnosed. Each year, there are approximately 280,000 new diagnoses of melanoma, approximately half of which have BRAF mutations, according to Novartis.

Dabrafenib plus trametinib is currently approved for indications in melanoma and non-small cell lung cancer.